73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Pulse Biosciences Inc
Closed
SectorHealthcare
13.7 -0.94
Overview
Share price change
24h
Min
13.45
Max
13.83
Income | -217K -19M |
|---|---|
Sales | 86K 86K |
EPS | -0.29 |
Profit margin | -22,540.698 |
Employees | 75 |
EBITDA | -228K -19M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +69.92% upside |
Next Earnings | 26 Mar 2026 |
|---|
Market Cap | -179M 958M |
|---|---|
Previous open | 14.64 |
Previous close | 13.7 |
News Sentiment
By Acuity
34%
66%
83 / 352 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Pulse Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pulse Biosciences Inc Forecast
Price Target
By TipRanks
69.92% upside
12 Months Forecast
Average 23.5 USD 69.92%
High 25 USD
Low 22 USD
Based on 2 Wall Street analysts offering 12 month price targets forPulse Biosciences Inc - Dist in the last 3 months.
Sentiment
By Acuity
83 / 352 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Live chat